<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tinzaparin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet"/></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tinzaparin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tinzaparin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11096" href="/d/html/11096.html" rel="external">see "Tinzaparin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868419"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Innohep</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F228132"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Low Molecular Weight Heparin</li></ul></div>
<div class="block doa drugH1Div" id="F228100"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d422ba0-a8b1-4eff-9688-3d0350b017f9">Anticoagulant in extracorporeal circuit during hemodialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulant in extracorporeal circuit during hemodialysis (recommendations apply to stable patients with chronic renal failure):</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dialysis session ≤4 hours (no hemorrhage risk):</i> Initial bolus (via arterial side of circuit or IV): 4,500 anti-Xa units at beginning of dialysis; typically achieves plasma concentrations of 0.5 to 1 anti-Xa units/mL; may give larger bolus for dialysis sessions &gt;4 hours. For subsequent dialysis sessions, may adjust dose as necessary in increments of 500 anti-Xa units based on previous outcome.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dialysis session &gt;4 hours (hemorrhage risk):</i> Initial bolus (IV only): 2,250 anti-Xa units at beginning of dialysis (do not add to dialysis circuit). A smaller second IV dose may be administered during dialysis sessions &gt;4 hours. For subsequent dialysis sessions, adjust dose as necessary to achieve plasma concentrations of 0.2 to 0.4 anti-Xa units/mL.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="063758a5-8975-48e6-963a-8203e8318448">Mechanical prosthetic heart valve to bridge anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanical prosthetic heart valve (aortic or mitral position) to bridge anticoagulation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Bridging during intervals of subtherapeutic anticoagulation should be considered for patients with mechanical mitral or tricuspid valve replacement; however, for patients with mechanical aortic valve replacement, bridging is not required unless an additional thromboembolic risk factor is present or patient has an older generation mechanical aortic valve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 175 anti-Xa units/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315266'])">Ref</a></span>); dose may be adjusted perioperatively based on anti-factor Xa monitoring (eg, for surgeries/procedures with high bleeding risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35964704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35964704'])">Ref</a></span>). For additional information regarding anti-factor Xa monitoring, refer to the "Reference Range" field. If patient is to undergo an invasive procedure, the last dose should be given ~24 hours prior to the procedure; reinitiate therapy ≥24 hours after the procedure when bleeding risk is acceptable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35964704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35964704'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9a047b1-b986-48a3-abb0-5ccd3dd3f7c9">Venous thromboembolism prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bariatric surgery, </i>
<i>moderate to </i>
<i>high venous thromboembolism risk (off-label use): </i>Based on limited evidence: <b>SUBQ</b>
<b>:</b> Initial: 75 anti-Xa units/kg once daily starting on postoperative day 1 (minimum dose: 4,500 anti-Xa units once daily and maximum dose: 14,000 anti-Xa units once daily); round dose to the closest possible syringe size; duration of therapy is typically 10 days postoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Douketis.1','lexi-content-ref-30099852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Douketis.1','lexi-content-ref-30099852'])">Ref</a></span>). <b>Note:</b> Optimal duration of prophylaxis is unknown, but is usually continued until hospital discharge and may be extended for up to 6 weeks postoperatively depending upon venous thromboembolism (VTE) risk. There is no consensus on indications for extended prophylaxis following bariatric surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lim.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lim.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total hip arthroplasty:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Preoperative initiation regimen: <b>SUBQ</b>
<b>:</b> 50 anti-Xa units/kg given 2 hours preoperatively, followed by 50 anti-Xa units/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); guidelines recommend initiation of a low molecular weight heparin (eg, tinzaparin) ≥12 hours preoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265'])">Ref</a></span>); clinical practice may differ on timing of initiation, refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">Postoperative initiation regimen: <b>SUBQ</b>
<b>:</b> 75 anti-Xa units/kg once daily, with initial dose given ≥12 hours postoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-Manu.1'])">Ref</a></span>); clinical practice may differ on timing of initiation, refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: Optimal duration of prophylaxis is unknown, but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total knee arthroplasty:</i>
<b>SUBQ</b>
<b>:</b> 75 anti-Xa units/kg once daily, with initial dose given ≥12 hours preoperatively <b>or</b> ≥12 hours postoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-Manu.1'])">Ref</a></span>). Body weight dosing using prefilled syringes may also be considered, refer to manufacturer labeling for detailed dosing recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: Optimal duration of prophylaxis is unknown, but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medical patients with acute illness at moderate and high risk for venous thromboembolism (off-label use):</i>
<b>SUBQ</b>
<b>:</b> 4,500 anti-Xa units once daily; continue for length of hospital stay or until patient is fully ambulatory and risk of VTE has diminished (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315261','lexi-content-ref-Thrombosis.Canada.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315261','lexi-content-ref-Thrombosis.Canada.2020'])">Ref</a></span>). Extended prophylaxis beyond acute hospital stay is not routinely recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315261','lexi-content-ref-22863355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315261','lexi-content-ref-22863355'])">Ref</a></span>). However, in high-risk coronavirus disease 2019 (COVID-19) patients who are discharged from the hospital, some experts would consider extended prophylaxis with a direct oral anticoagulant (DOAC) (eg, rivaroxaban) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cuker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cuker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General surgery:</i>
<b>SUBQ</b>
<b>:</b> 3,500 anti-Xa units once daily, with initial dose given 2 hours prior to surgery and then continued postoperatively for 7 to 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="467848a8-efa6-49a6-bc0d-47600b8b1418">Venous thromboembolism treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For timing of initiating oral anticoagulant, see <b>Transitioning between anticoagulants.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Deep vein thrombosis and/or pulmonary embolism treatment</b>:</i>
<b>SUBQ</b>
<b>:</b> 175 anti-Xa units/kg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapeutic anticoagulation (first episode, general recommendations):</i> Optimal duration of therapy is unknown and depends on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preference.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Provoked venous thromboembolism:</i> 3 months (provided the provoking risk factor is no longer present) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Unprovoked venous thromboembolism or provoked venous thromboembolism with a persistent risk factor:</i> ≥3 months depending on risk of VTE recurrence and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-22332937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-22332937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Venous thromboembolism treatment in patients with active cancer</b>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Months 1 to 6: </i>
<b>SUBQ:</b> Initial: 175 anti-Xa units/kg once daily for a total duration of 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31381464','lexi-content-ref-Bauer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31381464','lexi-content-ref-Bauer.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance beyond 6 months: </i>ACCP and ASCO guidelines for VTE prophylaxis/treatment recommend considering continuing anticoagulation beyond 6 months in select patients due to the persistent high risk of recurrence in those with active cancer; consider risk vs benefit of bleeding and recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-31381464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-31381464'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between anticoagulants: Note:</b> This provides general guidance on transitioning between anticoagulants; also refer to local protocol(s) for additional detail:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to tinzaparin:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic IV unfractionated heparin infusion to therapeutic-dose tinzaparin: Discontinue unfractionated heparin (UFH) and begin tinzaparin within 1 hour. <b>Note:</b> If aPTT is not in therapeutic range at the time UFH is discontinued, consult local protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nutescu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nutescu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from tinzaparin to another anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose tinzaparin to therapeutic IV unfractionated heparin infusion: Start IV UFH (rate based on indication) 1 to 2 hours before the next dose of tinzaparin would have been due. <b>Note:</b>
<b>Omit</b> IV UFH loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nutescu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nutescu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from prophylactic tinzaparin to therapeutic IV unfractionated heparin: UFH should be started without delay. A UFH bolus/loading dose may be used if indicated.</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose tinzaparin to warfarin: Start warfarin and continue tinzaparin until INR is within therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wittkowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wittkowsky.1'])">Ref</a></span>). <b>Note:</b> Overlap tinzaparin with warfarin until INR is ≥2 for at least 2 measurements taken ~24 hours apart (duration of overlap is ~5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from therapeutic-dose tinzaparin to a direct oral anticoagulant: Start direct oral anticoagulant within 2 hours prior to the next scheduled dose of tinzaparin.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991052"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>In patients with kidney impairment (eg, CrCl &lt; 30 mL/minute) anti-Xa levels may be used to monitor anticoagulant effects although they remain a poor predictor of hemorrhage risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16999658','lexi-content-ref-31721053','lexi-content-ref-17393021','lexi-content-ref-12167068','lexi-content-ref-33464938','lexi-content-ref-32786035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16999658','lexi-content-ref-31721053','lexi-content-ref-17393021','lexi-content-ref-12167068','lexi-content-ref-33464938','lexi-content-ref-32786035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to &lt;30 mL/minute: No dosage adjustment necessary; however, use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Although substantial accumulation of anti-Xa trough levels has not been observed following up to 14 days of tinzaparin therapy, the risk of bleeding may be increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16999658','lexi-content-ref-31721053','lexi-content-ref-Lim2016a','lexi-content-ref-Lim2016b','lexi-content-ref-17393021','lexi-content-ref-12167068','lexi-content-ref-30554045','lexi-content-ref-32786035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16999658','lexi-content-ref-31721053','lexi-content-ref-Lim2016a','lexi-content-ref-Lim2016b','lexi-content-ref-17393021','lexi-content-ref-12167068','lexi-content-ref-30554045','lexi-content-ref-32786035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Use of alternative agents should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). If use of tinzaparin deemed necessary, no dosage adjustment is likely necessary based on data in small, prospective observational studies that used up to 8 days of tinzaparin therapy, although risk of bleeding may be increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lim2016a','lexi-content-ref-30554045','lexi-content-ref-21819539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lim2016a','lexi-content-ref-30554045','lexi-content-ref-21819539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (large molecular weight):</p>
<p style="text-indent:-2em;margin-left:4em;">For most indications (eg, thrombosis treatment/prophylaxis), use of alternative agents should be considered. If use of tinzaparin is deemed necessary, no initial dosage adjustment is necessary; however, risk of bleeding is increased. Monitor closely for bleeding and utilize anti-Xa monitoring when applicable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Lim2016a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Lim2016a'])">Ref</a></span>). No dosage adjustment is necessary when used intravenously for anticoagulation of the extracorporeal circuit during hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (large molecular weight): Use of alternative agents should be considered. If use of tinzaparin is deemed necessary, no initial dosage adjustment is necessary; however, monitor closely for bleeding and utilize anti-Xa monitoring when applicable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT or PIRRT (eg, sustained, low-efficiency diafiltration): SUBQ: </b>Use of alternative agents should be considered. If use of tinzaparin is deemed necessary, no initial dosage adjustment is necessary; however, monitor closely for bleeding and utilize anti-Xa monitoring when applicable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988288"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Does not undergo hepatic metabolism; however, has been associated with transient increases in transaminase levels; use with caution.</p></div>
<div class="block doo drugH1Div" id="F20331239"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Specific dosing recommendations may not be available for all indications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">BMI 30 to 39 kg/m<sup>2</sup>: Use standard prophylaxis dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">BMI ≥40 kg/m<sup>2</sup>: Increase standard prophylaxis dose by 30% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19458109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19458109'])">Ref</a></span>); however, the ideal dose is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism treatment: </b>Use actual body weight to calculate dose; a fixed upper dose limit is not recommended; however, increased monitoring and dosage adjustment based on anti-Xa levels may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19458109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19458109'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F228101"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; clearance of tinzaparin may be reduced in elderly patients. Increased sensitivity to tinzaparin in elderly patients may be possible due to a decline in renal function.</p></div>
<div class="block dop drugH1Div" id="F14639839"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mg of tinzaparin equals 70 to 120 units of anti-Xa activity</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc833446-21e4-4fa4-b4a8-a0ded57b0b93">Deep vein thrombosis and/or pulmonary embolism treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis and/or pulmonary embolism treatment (off-label dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>):</b> SubQ: Infants, Children, and Adolescents: <b>Note:</b> May initiate a vitamin K antagonist on day 1 of tinzaparin therapy; discontinue tinzaparin on day 6 or later if INR is not &gt;2.</p>
<p style="text-indent:-2em;margin-left:4em;">Birth to 2 months: 275 anti-Xa units/kg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">2 to 12 months: 250 anti-Xa units/kg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 5 years: 240 anti-Xa units/kg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">5 to 10 years: 200 anti-Xa units/kg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 16 years: 175 anti-Xa units/kg once daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192775"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, use with caution; tinzaparin primarily undergoes renal elimination and clearance is decreased in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51192776"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, use with caution; does not undergo hepatic metabolism; however, has been associated with transient increases in transaminase levels.</p></div>
<div class="block adr drugH1Div" id="F228066"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1%), nausea (2%), vomiting (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (1%), urinary tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hematoma, hemorrhage (2%; major hemorrhage ≤3%, including intracranial hemorrhage, retroperitoneal hemorrhage)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (including hematoma at injection site [prophylaxis dosing: &lt;5%, treatment dosing: 10%], irritation at injection site, pain at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%), pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), epistaxis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Heparin-induced thrombocytopenia (type I, type II), thrombocythemia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, alopecia (Sarris 2003), bullous dermatitis (including hemorrhagic [Roy 2020]), ecchymoses, erythematous rash, maculopapular rash, pruritus, skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Purnell 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteopenia, osteoporosis</p></div>
<div class="block coi drugH1Div" id="F228081"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to tinzaparin, heparin, or other low molecular weight heparins (LMWH), or any component of the formulation; active bleeding from a local lesion such as an acute ulcer (eg, gastric, duodenal) or ulcerating carcinoma; history of confirmed or suspected immunologically mediated heparin-induced thrombocytopenia (HIT) or positive in vitro platelet-aggregation test in the presence of tinzaparin; acute or subacute septic endocarditis; active major hemorrhage or conditions/diseases involving increased risk of hemorrhage (eg, severe hepatic insufficiency, imminent abortion); hemophilia or major blood clotting disorders; acute cerebral insult or hemorrhagic cerebrovascular accidents without systemic emboli; uncontrolled severe hypertension; diabetic or hemorrhagic retinopathy; injury or surgery involving the brain, spinal cord, eyes or ears; spinal/epidural anesthesia in patients requiring treatment dosages of tinzaparin; use of multi-dose vials containing benzyl alcohol in children &lt;3 years of age, premature infants, and neonates.</p></div>
<div class="block war drugH1Div" id="F228063"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Monitor patient closely for signs or symptoms of bleeding, which may occur at any site. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; history of hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmology surgery; those concomitantly treated with drugs that increase the risk of bleeding (eg, antiplatelet agents, anticoagulants); recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Withhold or discontinue for minor bleeding. Protamine infusion may be necessary for serious bleeding (consult Protamine monograph for dosing recommendations).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by suppressing aldosterone production; similar reactions could occur with LMWHs. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, diabetes, renal dysfunction, preexisting metabolic acidosis, concomitant use of potassium-sparing diuretics or potassium supplements, long-term use of tinzaparin, and hematoma in body tissues).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Cases of thrombocytopenia including thrombocytopenia with thrombosis have occurred. Use with caution in patients with history of thrombocytopenia (drug-induced or congenital) or platelet defects; monitor platelet count closely. Use is contraindicated in patients with history of confirmed or suspected heparin-induced thrombocytopenia (HIT) or positive in vitro test for antiplatelet antibodies in the presence of tinzaparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytosis: Asymptomatic thrombocytosis has been observed with use, particularly in patients undergoing orthopedic surgery or with concurrent inflammatory process; discontinue use with increased platelet counts and evaluate the risks/necessity of further therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI ulceration: Use with caution in patients with history of GI ulcer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in hepatic impairment; associated with transient, dose-dependent increases in AST/ALT/GGT which typically resolve within 2 to 4 weeks of therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prosthetic heart valves: Prosthetic valve thrombosis has been reported in patients receiving thromboprophylaxis therapy with LMWHs. Pregnant women may be at increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in severe renal impairment; clearance is decreased in patients with CrCl ≤50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution due to increased bleeding risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: In patients receiving bridging anticoagulation with therapeutic dose tinzaparin, the last dose should be administered ~24 hours prior to the surgery/procedure; reinitiate therapy ≥24 hours after the surgery/procedure when bleeding risk is acceptable (ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extreme body weights: Use with caution in patients &lt;45 kg or &gt;120 kg; limited experience in these patients. Individualized clinical and laboratory monitoring are recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and should not be used in pregnant women. In neonates, large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”); the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porcine intestinal mucosa: This product is derived from porcine intestinal mucosa and should not be used in patients allergic to pork products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Some dosage forms contain sodium metabisulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is observed more frequently in asthmatics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For subcutaneous use only (except in hemodialysis patients); do not administer IM and avoid IM administration of other medications due to the risk of hematoma formation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuraxial anesthesia: Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal) or spinal puncture in patients anticoagulated with LMWH or heparinoids. Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as traumatic or repeated epidural or spinal punctures. Optimal timing between neuraxial procedures and tinzaparin administration is not known. Delay placement or removal of catheter for at least 12 hours after administration of the last prophylactic dose and at least 24 hours after the last treatment dose of tinzaparin; consider doubling these times in patients with creatinine clearance &lt;30 mL/minute. Risk of neuraxial hematoma may still exist since antifactor Xa levels are still detectable at these time points. Consider holding the next tinzaparin dose for 24 hours if the spinal puncture caused trauma. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia. If neurological compromise is noted, urgent treatment is necessary. If spinal hematoma is suspected, diagnose and treat immediately; spinal cord decompression may be considered although it may not prevent or reverse neurological sequelae.</p></div>
<div class="block dosfc drugH1Div" id="F48869015"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Innohep is manufactured from products derived from porcine intestinal mucosa.</p></div>
<div class="block geq drugH1Div" id="F52935269"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52868420"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Innohep: 10000 units/mL (2 mL); 20000 units/mL (2 mL) [contains benzyl alcohol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Innohep: 2500 units/0.25 mL (0.25 mL); 3500 units/0.35 mL (0.35 mL); 4500 units/0.45 mL (0.45 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Innohep: 8000 units/0.4 mL (0.4 mL); 10,000 units/0.5 mL (0.5 mL); 12,000 units/0.6 mL (0.6 mL); 14,000 units/0.7 mL (0.7 mL); 16,000 units/0.8 mL (0.8 mL); 18,000 units/0.9 mL (0.9 mL) [contains sodium metabisulfite]</p></div>
<div class="block adm drugH1Div" id="F228078"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ:</b> Patient should be lying down or sitting. Administer by deep SubQ injection into the lower abdomen (avoiding navel area), outer thigh, lower back, or upper arm. Do not administer IM. Injection site should be varied daily. To minimize bruising, do not rub the injection site.</p>
<p style="text-indent:-2em;margin-left:2em;">During hemodialysis, may be administered into the arterial side of the dialyzer circuit or IV in patients with no hemorrhage risk. In patients at risk of hemorrhage, administer IV only (do not add to the dialyzer circuit).</p></div>
<div class="block admp drugH1Div" id="F52613933"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: For SubQ administration; do not administer IM. Administer by deep SubQ injection; in adults, it is recommended to alternate between the lower abdomen (avoiding navel area), outer thigh, lower back, or upper arm. Injection site should be varied daily. To minimize bruising, do not rub the injection site.</p></div>
<div class="block use drugH1Div" id="F228076"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not available in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulation in extracorporeal circuit during hemodialysis: </b>Prevention of clotting in indwelling intravenous lines and extracorporeal circuit during hemodialysis (in patients without high bleeding risk).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis/pulmonary embolus (treatment):</b> Treatment of deep vein thrombosis and/or pulmonary embolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative thromboprophylaxis: </b> Prevention of venous thromboembolism (VTE) following orthopedic surgery or following general surgery in patients at high risk of VTE.</p></div>
<div class="block off-label drugH1Div" id="F50754688"><span class="drugH1">Use: Off-Label: Adult</span><p>Mechanical prosthetic heart valve (aortic or mitral position) to bridge anticoagulation; Venous thromboembolism prophylaxis, bariatric surgery (moderate to high venous thromboembolism risk); Venous thromboembolism prophylaxis, medical patients with acute illness at moderate and high risk for venous thromboembolism</p></div>
<div class="block mst drugH1Div" id="F5977828"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tinzaparin may be confused with Tinza (international brand name for nizatidine).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300143"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F228068"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithrombin: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the adverse/toxic effect of Tinzaparin. Specifically, the risk of bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56512917"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients undergoing assisted reproduction therapy (ART) may be at increased risk for thrombosis. Venous thromboembolism prophylaxis is not routinely recommended for patients undergoing ART; however, prophylactic doses of low-molecular-weight heparin (LMWH) are recommended for patients who develop severe ovarian hyperstimulation syndrome (ACCP [Bates 2012]; ASH [Bates 2018]; SOGC [Shmorgun 2017]). In addition, prophylactic doses of LMWH are recommended in patients undergoing ART who have a positive antiphospholipid antibody test but are not diagnosed with antiphospholipid syndrome (APS), as well as patients diagnosed with obstetric APS. Therapeutic doses of LMWH are recommended in patients undergoing ART diagnosed with thrombotic APS (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F228084"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tinzaparin does not cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of fetal bleeding or teratogenic effects has not been reported (ACCP [Bates 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of low-molecular-weight heparin (LMWH) may be altered; dosing adjustment may be required. Prophylactic doses of LMWH may also need modified in pregnant patients at extremes of body weight (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Use is contraindicated in conditions involving increased risks of hemorrhage, including patients with imminent abortion.</p>
<p style="text-indent:0em;margin-top:2em;">The risk of venous thromboembolism (VTE) is increased in pregnant patients, especially during the third trimester and first week postpartum. LMWH is recommended over unfractionated heparin for the treatment of acute VTE in pregnant patients. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant patients with certain risk factors (eg, homozygous factor V Leiden, antiphospholipid antibody syndrome with ≥3 previous pregnancy losses) (ACCP [Bates 2012]; ACOG 2018; ASH [Bates 2018]; ESC [Regitz-Zagrosek 2018]). LMWH may also be considered for VTE prophylaxis in pregnant patients with COVID-19 (NIH 2023). Consult current recommendations for appropriate use in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">LMWH may be used prior to cesarean delivery in patients with additional risk factors for developing VTE. Risk factors may include a personal history of deep vein thrombosis or pulmonary embolism, inherited thrombophilia, or patients with class III obesity (Pacheco 2020).</p>
<p style="text-indent:0em;margin-top:2em;">LMWH may also be used in pregnant patients with mechanical heart valves. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered. Patients with mechanical heart valves have an increased risk of adverse fetal and maternal outcomes (including valve thrombosis), and these risks are greater without appropriate anticoagulation. Increased monitoring of anti-factor Xa levels is required; frequent dose titration may be needed to maintain adequate therapeutic anti-factor Xa concentrations during pregnancy (consult current recommendations for details) (ACC/AHA [Otto 2021]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Multiple-dose vials contain benzyl alcohol (avoid use in pregnant patients due to association with gasping syndrome in premature infants); use of preservative-free formulation is recommended.</p></div>
<div class="block brc drugH1Div" id="F14182386"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tinzaparin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Small amounts of another low-molecular-weight heparin (LMWH) have been detected in breast milk; however, because they have a low oral bioavailability, LMWHs are unlikely to cause adverse events in a breastfeeding infant. According to the manufacturer, caution should be used if administered to a breastfeeding patient. LMWH is considered compatible with breastfeeding (ACCP [Bates 2012]; ACOG 2018; ASH [Bates 2018]).</p></div>
<div class="block mop drugH1Div" id="F228073"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with platelet count (at baseline then periodically throughout therapy); renal function (use Cockcroft-Gault formula); hepatic function; potassium (baseline and regularly thereafter in patients at risk for hyperkalemia); stool for occult blood. Routine monitoring of anti-Xa levels is generally not recommended; however, anti-Xa levels may be beneficial in certain patients (eg, children, obese patients, patients with severe renal insufficiency receiving therapeutic doses, and possibly pregnant women receiving therapeutic doses) (ACCP [Guyatt 2012]). Peak anti-Xa levels are measured 4 to 6 hours after administration. Monitoring of PT and/or aPTT is not recommended.</p></div>
<div class="block rer drugH1Div" id="F14182843"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-Xa level (measured 4 hours after administration): Fixed-dose (3,500 units): 0.15 anti-Xa units/mL; weight-based (75 to 175 units/kg): 0.34 to 0.70 anti-Xa units/mL; in treatment of venous thromboembolism, a target of 0.85 anti-Xa units/mL has been recommended (Garcia 2012)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Children: Target anti-Xa level: 0.5 to 1 anti-Xa units/mL 4 to 6 hours after administration or 0.5 to 0.8 anti-Xa units/mL 2 to 6 hours after administration (Monagle 2012)</p></div>
<div class="block pha drugH1Div" id="F228062"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tinzaparin is a low molecular weight heparin (average molecular weight ranges between 5,500 and 7,500 daltons, distributed as &lt;2,000 daltons [&lt;10%], 2,000 to 8,000 daltons [60% to 72%], and &gt;8,000 daltons [22% to 36%]) that binds antithrombin III, enhancing the inhibition of several clotting factors, particularly factor Xa. Tinzaparin anti-Xa activity (70 to 120 units/mg) is greater than anti-IIa activity (~55 units/mg) and it has a higher ratio of antifactor Xa to antifactor IIa activity compared to unfractionated heparin. Low molecular weight heparins have a small effect on the activated partial thromboplastin time.</p></div>
<div class="block phk drugH1Div" id="F228080"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Values reflective of anti-Xa activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Detectable anti-Xa activity persists for 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slow; absorption half-life ~3 hours after subcutaneous administration</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Does not undergo hepatic metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: ~90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 82 minutes; prolonged in renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F228085"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Innohep | Tinzaparin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Innohep | Tinzaparin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Innohep</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):S44-S88. doi:10.1378/chest.11-2292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists' (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi:10.1111/j.1538-7836.2012.04662.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315276">
<a name="22315276"></a>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):e691-e736. doi:10.1378/chest.11-2300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315276/pubmed" id="22315276" target="_blank">22315276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482767">
<a name="30482767"></a>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Adv</i>. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/30482767/pubmed" id="30482767" target="_blank">30482767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.2019">
<a name="Bauer.2019"></a>Bauer KA. Anticoagulation therapy for VTE (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/venous-thromboembolism-anticoagulation-after-initial-management?search=Venous%20thromboembolism:%20Anticoagulation%20after%20initial%20management&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuker.1">
<a name="Cuker.1"></a>Cuker A, Peyvandi F. Coronavirus disease 2019 (COVID-19): hypercoagulability. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Douketis.1">
<a name="Douketis.1"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315266">
<a name="22315266"></a>Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e326S-e350S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315266/pubmed" id="22315266" target="_blank">22315266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20735722">
<a name="20735722"></a>Erkens PM, Gandara E, Wells P, et al. Safety of outpatient treatment in acute pulmonary embolism. <i>J Thromb Haemost</i>. 2010;8(11):2412-2417. doi:10.1111/j.1538-7836.2010.04041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/20735722/pubmed" id="20735722" target="_blank">20735722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e278S-e325S. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):24-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16999658">
<a name="16999658"></a>George-Phillips KL, Bungard TJ. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. <i>Pharmacotherapy</i>. 2006;26(10):1479-1490. doi:10.1592/phco.26.10.1479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/16999658/pubmed" id="16999658" target="_blank">16999658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315263">
<a name="22315263"></a>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e227-e277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315263/pubmed" id="22315263" target="_blank">22315263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12038783">
<a name="12038783"></a>Hainer JW, Barrett JS, Assaid CA, et al. Dosing in Heavy-weight/Obese Patients With the LMWH, Tinzaparin: A Pharmacodynamic Study. <i>Thromb Haemost</i>. 2002;87(5):817-823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/12038783/pubmed" id="12038783" target="_blank">12038783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31721053">
<a name="31721053"></a>Helfer H, Siguret V, Mahé I. Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications. <i>Am J Cardiovasc Drugs</i>. 2020;20(3):223-228. doi:10.1007/s40256-019-00382-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/31721053/pubmed" id="31721053" target="_blank">31721053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LEO.1">
<a name="LEO.1"></a>Innohep (tinzaparin) [product monograph]. Thornville, Ontario, Canada: LEO Pharma Inc; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315261">
<a name="22315261"></a>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e195S-e226S. doi:10.1378/chest.11-2296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315261/pubmed" id="22315261" target="_blank">22315261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi:10.1378/chest.11-2301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16926353">
<a name="16926353"></a>Kearon C, Ginsberg JS, Julian JA, et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. <i>JAMA</i>. 2006;296(8):935-942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/16926353/pubmed" id="16926353" target="_blank">16926353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21477846">
<a name="21477846"></a>Leizorovicz A, Siguret V, Mottier D. Safety Profile of Tinzaparin versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis: The Innohep® in Renal Insufficiency Study (IRIS). <i>Thromb Res</i>. 2011;128(1):27-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/21477846/pubmed" id="21477846" target="_blank">21477846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lim2016a">
<a name="Lim2016a"></a>Lim W, Crowther M, Wang L, et al. Assessment of low molecular weight heparin accumulation in patients with chronic kidney disease: results from the TRIVET study [abstract]. <i>J Thromb Haemost</i>. 2016a:14 (suppl 1):S1-S168. doi:10.1111/jth.13325</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lim2016b">
<a name="Lim2016b"></a>Lim W, Crowther M, Wang L, et al. Serial trough anti-Xa levels to assess low molecular weight heparin accumulation in patients with chronic kidney disease: analysis of CrCl &lt;30 ml/min from the Trivet Study. <i>Blood.</i> 2016b;128(22):90. doi:10.1182/blood.V128.22.90.90</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lim.1">
<a name="Lim.1"></a>Lim RB. Bariatric operations: Early (fewer than 30 days) morbidity and mortality. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17393021">
<a name="17393021"></a>Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. <i>Thromb Haemost</i>. 2007;97(4):581-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/17393021/pubmed" id="17393021" target="_blank">17393021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan A, Goldenberg NA, et al. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). <i>Chest</i>. 2012;141(2)(suppl):e737-e801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12627937">
<a name="12627937"></a>Nagge J, Jackevicius C, Dzavik V, et al. Acute Profound Thrombocytopenia Associated With Eptifibatide Therapy. <i>Pharmacotherapy</i>. 2003;23(3):374-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/12627937/pubmed" id="12627937" target="_blank">12627937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated April 20, 2023. Accessed May 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nutescu.1">
<a name="Nutescu.1"></a>Nutescu EA, Dager W. Heparin, low molecular weight heparin, and fondaparinux. In: Gulseth M, ed. <i>Managing Anticoagulation Patients in the Hospital.</i> American Society of Health-System Pharmacists; 2007:181.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19458109">
<a name="19458109"></a>Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. <i>Ann Pharmacother</i>. 2009;43(6):1064-1083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/19458109/pubmed" id="19458109" target="_blank">19458109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32360109">
<a name="32360109"></a>Pacheco LD, Saade G, Metz TD; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine consult series #51: thromboembolism prophylaxis for cesarean delivery. <i>Am J Obstet Gynecol</i>. 2020;223(2):B11-B17. doi:10.1016/j.ajog.2020.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/32360109/pubmed" id="32360109" target="_blank">32360109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12167068">
<a name="12167068"></a>Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. <i>Drug Saf</i>. 2002;25(10):725-733. doi:10.2165/00002018-200225100-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/12167068/pubmed" id="12167068" target="_blank">12167068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30554045">
<a name="30554045"></a>Projean D, Lalonde S, Morin J, et al. Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - the STRIP study. <i>Thromb Res</i>. 2019;174:48-50. doi:10.1016/j.thromres.2018.11.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/30554045/pubmed" id="30554045" target="_blank">30554045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11736885">
<a name="11736885"></a>Richter C, Sitzmann J, Lang P, et al. Excretion of low molecular weight heparin in human milk. <i>Br J Clin Pharmacol</i>. 2001;52(6):708-710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/11736885/pubmed" id="11736885" target="_blank">11736885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863355">
<a name="22863355"></a>Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? <i>J Thromb Haemost</i>. 2012;10(10):2053-2060. doi:10.1111/j.1538-7836.2012.04874.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22863355/pubmed" id="22863355" target="_blank">22863355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-the diagnosis and management of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi:10.1016/j.jogc.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21819539">
<a name="21819539"></a>Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. <i>J Thromb Haemost</i>. 2011;9(10):1966-1972. doi:10.1111/j.1538-7836.2011.04458.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/21819539/pubmed" id="21819539" target="_blank">21819539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9278462">
<a name="9278462"></a>Simonneau G, Sors H, Charbonnier B, et al. A Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin for Acute Pulmonary Embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. <i>N Engl J Med</i>. 1997;337(10):663-669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/9278462/pubmed" id="9278462" target="_blank">9278462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thrombosis.Canada.2020">
<a name="Thrombosis.Canada.2020"></a>Thombosis Canada. Thromboprophylaxis: hospitalized medical patients. https://thrombosiscanada.ca/wp-content/uploads/2020/03/Thromboprophylaxis-Medical-Patients-24March2020-1.pdf. Published March 24, 2020. Accessed October 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30099852">
<a name="30099852"></a>Tseng EK, Kolesar E, Handa P, et al. Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. <i>J Thromb Haemost.</i> 2018;16(10):2008-2015. doi:10.1111/jth.14263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/30099852/pubmed" id="30099852" target="_blank">30099852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33464938">
<a name="33464938"></a>Vathiotis IA, Syrigos NK, Dimakakos EP. Tinzaparin safety in patients with cancer and renal impairment: a systematic review. <i>Clin Appl Thromb Hemost</i>. 2021;27:1076029620979592. doi:10.1177/1076029620979592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/33464938/pubmed" id="33464938" target="_blank">33464938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320387">
<a name="11320387"></a>Warkentin TE, Kelton JG. Temporal Aspects of Heparin-Induced Thrombocytopenia. <i>N Engl J Med</i>. 2001;344(17):1286-1292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/11320387/pubmed" id="11320387" target="_blank">11320387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wittkowsky.1">
<a name="Wittkowsky.1"></a>Wittkowsky AK. Warfarin. In: <i>Anticoagulation Therapy: A Clinical Practice Guide, 2ed</i>. Dager W, ed. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32786035">
<a name="32786035"></a>Yeung J, Dix CHK, Ritchie AG, Kow M, Chen VMY. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study. <i>Intern Med J</i>. 2023;53(1):68-73. doi:10.1111/imj.15010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/32786035/pubmed" id="32786035" target="_blank">32786035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315271">
<a name="22315271"></a>You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):S531-S575. doi:10.1378/chest.11-2304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinzaparin-united-states-not-available-drug-information/abstract-text/22315271/pubmed" id="22315271" target="_blank">22315271</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10009 Version 220.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
